[Investigation of the prevalence of visceral leishmaniasis by the microculture method and IFAT in dogs in Kirikkale.]. / Kirikkale'deki Köpeklerde Mikrokültür Yöntemi ve IFAT ile Visseral Leishmaniosisin Prevalansinin Arastirilmasi.

This study was carried out in order to compare the seroprevalence of visceral leishmaniasis in dogs from different areas of Kirikkale between 2006-2008 using the microculture method (MCM) which is a new method, and the indirect fluorescent antigen test (IFAT). All of the blood collected from total of 50 dogs was found to be negative by MCM. Only one male Beagle strain dog (3 years old) was found to be seropositive at 1/128 titers (2%) for anti-Leishmania infantum IgG antibodies by IFAT.

Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial.

Azithromycin, an azalide subclass macrolide antibiotic, is an effective, well-tolerated and safe therapeutic option for treatment of papillomatosis in humans. This study reports the clinical and histopathological results from a prospective, randomized, double-blinded, placebo-controlled trial of 17 dogs of various breeds with diagnosis of oral (n = 12) and cutaneous papillomatosis (n = 5) treated with azithromycin. Papillomas appeared as whitish, verrucous, hyperkeratotic papules 1-2.7 mm in size. The cases were randomly assigned to azithromycin (n = 10) and placebo treatment groups (n = 7). Both owners and investigators were blinded to the allocation to the groups. Azithromycin (10 mg/kg) was administered per os every 24 h for 10 days. Clinical evaluations were done by the same investigator throughout the trial. Azithromycin treatment significantly decreased clinical scores (P < 0.001), whereas there was no change seen in the placebo group. In the azithromycin treatment group, skin lesions disappeared in 10-15 days. One case in the placebo had spontaneous regression of its papillomas by day 41, but lesions were still evident at day 50 in the remaining six cases. There was no recurrence of papillomatosis in the azithromycin treated dogs (follow up 8 months). No adverse effects were seen in either group. In conclusion, azithromycin appears to be a safe and effective treatment for canine papillomatosis.